Skip to main content
Premium Trial:

Request an Annual Quote

Waters Says Q1 Sales Rise 8.2 Percent as R&D and Per-Share Profits Grow

NEW YORK, April 26 (GenomeWeb News) - Waters today reported that first-quarter sales rose 8.2 percent atop increasing R&D spending and a narrowed profit.


Total sales for the three months ended April 1 increased to $290.2 million from $268.3 million in the year-ago period.


R&D spending jumped to $19 million from $16.7 million year over year.


Profits for the quarter declined to $44.2 million from $46.6 million year over year though per-share income grew to $.42 from $.39.


Waters said it had around $481.2 million in cash and equivalents as of April 1.


"A favorable convergence of market factors including rapid uptake of our proprietary ACQUITY UPLC chromatography technology, robust business growth in India and China and the continued strength of our global industrial accounts, enabled us to perform at a level above our projections and provides a higher level of confidence for the year," Douglas Berthiaume, chairman, president, and CEO, said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.